Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran
The Phase III HELIOS-B study met its primary and secondary endpoints in the monotherapy and overall study populations.
![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/06/shutterstock_2194089933.jpg)
The Phase III HELIOS-B study met its primary and secondary endpoints in the monotherapy and overall study populations.
Since emerging from stealth in December 2023, the company has begun establishing its laboratories in Montreal.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Q&A with Springer Nature’s Leslie Lansman: Ethical content sharing and the benefits of the CLA Pharmaceutical Licence
Novavax seeks FDA approval for updated Covid-19 vaccine
Cyrus Biotechnology to spin out Levitate Bio for biopharma AI
Moderna applies for review of updated Covid-19 vaccine